FLOW Trial Journal Club
We break down evidence-based medicine so you don't have to! This journal club will discuss the new FLOW trial that has some landmark results you don't want to miss!
The New England Journal of Medicine published the FLOW trial in May 2024. This post is a journal club breaking down the FLOW trial and what change it may bring to our clinical practice.
Link to the trial on NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2403347Background/Overview
Title: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Citation: Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. NEJM May 2024;391(2):109-121.
Objective: To assess the efficacy and safety of subcutaneous semaglutide 1.0 mg once weekly for the prevention of kidney failure, substantial loss of kidney function, and death from kidney-related or cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.
Primary Efficacy Measure: Major kidney disease events, a composite of:
- onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 ml/min/1.73 m2 sustained for ≥28 days)
- a sustained (≥28 days) 50% or greater reduction in eGFR from baseline, or
- death from kidney-related or cardiovascular causes